Mar 1, 2019 · RPS6 inhibition decreases NRF2 expression and restores sensitivity in HER2-amplified gastric cancer in vitro and in vivo. High NRF2 expression in gastric cancer patients …

Mar 1, 2019 · We found RPS6 activation and NRF2 to be related to anti-HER2 drug resistance. RPS6 or NRF2 inhibition with siRNA reduced viability and resistance to anti-HER2 drugs. In …

Mar 7, 2024 · PI3K/AKT/mTOR/ribosomal protein S6 (RPS6)/nuclear factor erythroid 2-related factor 2 (NRF2) axis. The PI3K/AKT/mTOR pathway is a key pathway for inducing resistance …

Gambardella and coworkers found that NRF2 amplified the resistance to anti-HER2 drugs through the PI3K/AKT/mTOR/RPS6 pathway, and that ribosomal protein S6 (RPS6) inhibition …

In resistant cells, protein expression underlined the activation of PI3K pathway and of its downstream effector RPS6 protein. Analysing microarray, it was possible to identify, the …

Protein expression underlined the activation of PI3K pathway and of its downstream effector RPS6 protein. Data obtained by microarray were analysed, identifying a large number of …

NRF2 activation through RPS6 is related to resistance to both lapatinib and trastuzumab in . HER2. amplified gastric cancer models. Inhibition of RPS6 and NRF2. reduces cell viability . …

Conclusions: NRF2 through the PI3K/AKT/mTOR/RPS6 pathway could be a potential effector of resistance to anti-HER2 drugs in our models. RPS6 inhibition decreases NRF2

Nov 30, 2018 · RPS6 inhibition decreases NRF2 expression and restores sensitivity in HER2-amplified gastric cancer in vitro and in vivo. High NRF2 expression in gastric cancer patients …

To address whether RPS6 could be involved in NRF2 increase, a knockdown of RPS6 was performed. Western blot analysis highlighted the decrease of NRF2 expression in LR1OE …